Preventing transplant rejection with new treatment

Friday, 19 October, 2018

Preventing transplant rejection with new treatment

Transplant rejection could be prevented with a new treatment strategy, according to research from The University of Queensland.

The new approach removes the need for donor matching and the use of immunosuppressant drugs to prevent rejection, and could make stem cell treatment accessible to more patients.

UQ Diamantina Institute researcher Dr Jatin Patel said researchers found immunosuppressant drugs had a negative impact on transplanted stem cells.

“Patients receiving a donation of stem cells from an unrelated individual normally need to take medication to suppress their immune system to prevent rejection,” he said.

“When we injected stem cells to repair blood vessels, we noticed those cells were damaged by the immunosuppressant drugs.

“The stem cells did not work properly and the damaged blood vessels were not repaired.

“We found that without immunosuppression therapy, the delivered stem cells actually functioned better and may have a better likelihood of superior clinical outcomes for the patient.”

UQDI dermatologist Associate Professor Kiarash Khosrotehrani said the treatment could be used for patients with chronic wounds caused by diseases such as peripheral vascular disease and limb ischemia.

“Chronically ill patients with extensive lower limb wounds due to poor blood flow are generally unable to undergo invasive surgical procedures and end up with amputation,” Assoc Prof Khosrotehrani said.

“Our approach would reduce the burden of these chronic wounds by presenting an option for stem cell therapy without the worry of patients getting additional infections while taking immunosuppressive drugs.”

Dr Patel said the new treatment strategy harnesses the cells’ existing features.

“The strategy worked by combining two types of stem cells, one of which had ‘in-built’ immunosuppressant properties,” he said.

“When injected together, the stem cells survived and functioned without the need for immunosuppressant drugs.

“Our patented technology to isolate these two stem cell types gives us confidence that such therapy can be trialled in patients in the future.”

The study has been published in Stem Cells Translational Medicine.

Image caption: Stem cells (left) were used to create blood vessels (right).

Related News

Pandemic accelerates digital transformation by six years

Twilio's global study reveals that 97% of enterprise decision-makers believe the COVID-19...

Digital health micro-credentials to keep workforce up to speed

Three digital health courses will be delivered by RMIT Online and the Digital Health CRC to...

Project iRAD to expand in SW Sydney region

The innovative solution enables healthcare organisations to share patient-consented health...

  • All content Copyright © 2020 Westwick-Farrow Pty Ltd